Doctors are flagging a real concern for people living with ALS and other brain or nerve disorders: the same medications that can be game-changers for weight loss and diabetes may be a bad fit when the body is already fighting a degenerative disease. The warning centers on GLP-1 receptor agonists like Ozempic and Wegovy, which can drive rapid weight loss, something that may work against patients who need to preserve muscle, calories, and strength. In this case, the big picture matters just as much as the prescription.
Neurologists say the issue is not that these drugs are broadly unsafe. For many people, GLP-1 medications have delivered real benefits, especially for obesity and type 2 diabetes, and they have also been tied to improvements in cardiovascular risk, stroke risk, liver disease, and even addiction-related outcomes. The trouble starts when the patient’s condition changes the rules, because ALS is not a standard weight-loss situation.
Jinsy Andrews, MD, who directs the ALS Center at NYU Langone, says the biology of ALS makes calorie loss a bigger deal than it is for the average patient. In neurodegenerative disease, the body often needs every bit of energy it can get, and pushing weight down can speed the slide instead of helping it. That is a tough contrast, especially because the wider public usually hears that losing weight is always a win.
For ALS patients, maintaining weight is often part of good care, and in some cases gaining a little can be the goal. That sounds backward if you are used to hearing about diet culture and metabolic health, but ALS is a different battlefield. The disease can come with hypermetabolism, muscle wasting, and a shrinking margin of safety, so a medication that reduces body fat can become a problem fast.
Andrews said that in people with ALS, using GLP-1 drugs may actually worsen the disease and accelerate progression. That warning gets sharper when diabetes is also in the picture, because the instinct is often to treat one condition aggressively without thinking through how it might affect the other. In ALS, the body is already under strain, and a steep caloric deficit can push things in the wrong direction.
A case report published in 2025 added weight to that concern. A 52-year-old woman with ALS and type 2 diabetes was prescribed semaglutide, and while it was intended to help her blood sugar, the timeline that followed raised alarms. She lost 25 pounds in three months, and her physical decline suddenly worsened far more than expected.
Before semaglutide, her ALS progression had been moving at a more predictable pace on the standard rating scale used by clinicians. After the weight drop, her symptoms took a sharp turn, and the report described a dramatic acceleration in her deterioration. Once the drug was stopped, the rapid slide stabilized, which is exactly the kind of signal doctors do not want to ignore.
That one report is not the whole story, but it fits with a broader caution from specialists who treat neurodegenerative disease every day. Andrews noted that published cases and retrospective data should make clinicians pause before handing GLP-1 prescriptions to patients with ALS. In other words, the same medication can be a strong tool in one room and a dangerous mismatch in another.
This is where careful medicine beats one-size-fits-all thinking. A patient might need tight diabetes control, but if they also have ALS, the priority may shift toward preserving strength, function, and body mass. That means doctors need to look beyond lab numbers and weigh how the treatment affects the whole person, not just the glucose reading or the scale.
Manufacturers also stress that these medications were not built or labeled with ALS as a listed warning, and that they take adverse event reports seriously. Still, the absence of a warning label does not erase the clinical reality doctors are now talking about at the bedside. For patients facing a progressive neurologic illness, the conversation is becoming less about what a drug can do in theory and more about what it might cost in practice.
